Public Awareness and Acceptability of PGT-M in Cancer Predisposition Syndromes.
Davide CalosciLisa PassagliaIlaria GabbiatoFrancesca CartisanoRebecca AffusoUgo SorrentinoDaniela ZuccarelloPublished in: Genes (2023)
Cancer Predisposition Syndromes (CPSs), also known as Hereditary Cancer Syndromes (HCSs), represent a group of genetic disorders associated with an increased lifetime risk of developing cancer. In this article, we provide an overview of the reproductive options for patients diagnosed with CPS, focusing on the emerging role of Preimplantation Genetic Testing for Monogenic disorders (PGT-M). Specifically, we conducted a literature review about the awareness and acceptability of its application to CPSs. Based on the available data, the awareness of the applicability of PGT-M for CPSs appears to be limited among both patients and physicians, and a heterogeneous set of factors seems to influence the acceptability of the procedure. Our findings highlight the need for increasing education about the use of PGT-M for CPSs. In this context, guidelines developed by professional or institutional bodies would represent a useful reference tool to assist healthcare professionals in providing proper preconception counseling.
Keyphrases
- papillary thyroid
- end stage renal disease
- squamous cell
- healthcare
- ejection fraction
- newly diagnosed
- primary care
- prognostic factors
- peritoneal dialysis
- gene expression
- mental health
- squamous cell carcinoma
- lymph node metastasis
- emergency department
- hepatitis c virus
- patient reported outcomes
- genome wide
- patient reported
- quality improvement
- adverse drug